<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Nodify XL2 Test

Rule out malignancy prior to bronchoscopy.

Nodify XL2 testing is designed to help physicians identify likely benign lung nodules using a simple to use blood-based test for patients with low to moderate risk incidental lung nodules.

Nodify XL2™ testing can help stratify patients with incidental lung nodules by risk of malignancy, instilling confidence in the path forward for both patients and physicians.

Order Nodify XL2

Which Patients are right for Nodify XL2?

Nodify XL2 is intended for patients ≥40 years old with low to moderate risk nodules between 8-30 mm with ≤50% risk as assessed by the  Solitary Pulmonary Nodule Calculator (Mayo Model)1 .

Improving Nodule Management

  • A simple blood draw can be seamlessly incorporated into an existing workflow.
  • Swift results integrate a physician’s clinical assessment with circulating proteins associated with lung cancer.
  • More accurate risk assessment can reduce patient anxiety and support the most appropriate care path with confidence.
  • Nodify XL2 testing is covered by Medicare with $0 out of pocket expense for covered Medicare and Medicaid beneficiaries.

Clinically Validated Results

  • Evaluated with the PANOPTIC study2, a prospective, multicenter observational study for patients with low to moderate risk incidental lung nodules (≤ 50% risk of malignancy).
  • Median results showed a 98% negative predictive value (NPV) and a potential 40% reduction in invasive procedures on benign nodules.

READ THE PANOPTIC PUBLICATION
READ THE PANOPTIC EDITORIAL

Nodify XL2 Testing Can Help You

Simple, Integrated, Reassuring.

Stratify patients with incidental lung nodules with a swift, simple blood test prior to bronchoscopy.
Combine your clinical assessment with circulating protein biomarker results to help reliably rule out malignancy.
Confidently proceed with the most appropriate care path.

Nodify XL2 testing is covered by Medicare with $0 out of pocket expense for covered Medicare and Medicaid beneficiaries.

Learn more

Financial Assistance

We understand the financial stresses that health issues can place on patients. We have created a financial assistance program for patient with financial responsibility to assist in providing affordable care.

To learn more about our financial assistance program, please contact our Customer Care team at 1.866.432.5930.

Contact Us

Get in touch

Contact Us

Data Library

Discover More

1. Swensen SJ, Silverstein MD, Ilstrup DM, et. al. "The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules." Arch Intern Med. 1997 Apr 28; 157(8):849-55.

2. Silvestri G et al. "Assessment of plasma proteomics biomarkers ability to distinguish benign from malignant lung nodules." CHEST. 2018 Sept. 154(3):491-500.